Andrews, D A., Bonta, J., & Wormith, J. S. (2011). The risk-need-responsivity (RNR) model: Does adding the good lives model contribute to effective crime prevention? Criminal Justice and Behavior, 38(7), 735-755. https://doi.org/10.1177/0093854811406356
DJI (2024). Overzicht door DJI gecontracteerde aanbieders FZ per 1/1/2024 per zorgsoort. https://www.forensischezorg.nl/documenten/publicaties/2024/02/12/overzicht-aanbieders-fz-2024-per-zorgsoort
Douglas, K S., Hart, S. D., Webster, C. D., Belfrage, H., Guy, L. S., & Wilson, C. M. (2014). Historical-Clinical-Risk Management-20, Version 3 (HCR-20V3): Development and Overview. International Journal of Forensic Mental Health, 13, 93-108. https://doi.org/DOI: 10.1080/14999013.2014.906519
Drieschner, K , & Tollenaar, N. (2011). Recidive tijdens forensische zorgtrajecten 2013-2017. Cahier 2021-18. www.wodc.nl
Fazel S, Danesh J Serious mental disorder in 23000 prisoners: a systematic review of 62 surveys. Lancet. 2002 Feb 16;359(9306):545-50. doi: 10.1016/S0140-6736(02)07740-1.
Guyton, M R., & Foerschner, A. (2017). Treatment of Personality Disorders in Forensic/Correctional Settings. In R. Roesch & A. N. Cook (Eds.), Handbook of Forensic Mental Health Services (pp. 290-322). Routledge. https://doi.org/10.4324/9781315627823-11
ILOSTAT (2011). ISCED. International Standard Classification of Education. https://ilostat.ilo.org/resources/concepts-and-definitions/classification-education/
Jankovic M, Masthoff E, Spreen M, de Looff P, Bogaerts S A Latent Class Analysis of Forensic Psychiatric Patients in Relation to Risk and Protective Factors. Front Psychol. 2021 Jul 20;12:695354. doi: 10.3389/fpsyg.2021.695354. eCollection 2021.
Lutz M, Zani D, Fritz M, Dudeck M, Franke I A review and comparative analysis of the risk-needs-responsivity, good lives, and recovery models in forensic psychiatric treatment. Front Psychiatry. 2022 Oct 31;13:988905. doi: 10.3389/fpsyt.2022.988905. eCollection 2022.
Noland E, Strandh M Historical, clinical and situational risk factors for post-discharge recidivism in forensic psychiatric patients - A Swedish registry study. Int J Law Psychiatry. 2021 Nov-Dec;79:101749. doi: 10.1016/j.ijlp.2021.101749. Epub 2021 Nov 10.
Tamam L, Ozpoyraz N, Karatas G Personality disorder comorbidity among patients with bipolar I disorder in remission. Acta Neuropsychiatr. 2004 Jun;16(3):175-80. doi: 10.1111/j.1601-5215.2004.00074.x.
Taylor, J (2014). Developing a framework for the identification of criminogenic needs in offenders with intellectual disability and personality disorder: The Treatment Need Matrix. Advances in Mental Health and Intellectual Disabilities, 8(1), 43-50. https://doi.org/10.1108/AMHID-07-2013-0051
van den Bosch LM, Hysaj M, Jacobs P DBT in an outpatient forensic setting. Int J Law Psychiatry. 2012 Jul-Aug;35(4):311-6. doi: 10.1016/j.ijlp.2012.04.009. Epub 2012 May 5.
Verschuur, J , & Keulen-de Vos, M. (2018). Basis zorgprogramma voor de forensische ambulante zorg.
Yu R, Geddes JR, Fazel S Personality disorders, violence, and antisocial behavior: a systematic review and meta-regression analysis. J Pers Disord. 2012 Oct;26(5):775-92. doi: 10.1521/pedi.2012.26.5.775.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
